EUCTR2008-006871-60-DE进行中（未招募）不适用
Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma - DIRECTOR
niversity Hospital Heidelberg, Ruprechts-Karl-University Heidelberg0 个研究点目标入组 166 人开始时间: 2009年3月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Progressive or recurrent glioblastoma documented by MRI no earlier than 180 days after first surgery for glioblastoma and no earlier than 90 days after completion of radiotherapy.
- •Histological diagnosis of glioblastoma
- •Tissue available for the determination of MGMT gene promoter methylation in the recurrent tumor
- •Prior treatment with temozolomide administered concomitantly with radiotherapy and at least for two cycles (5/28) as an adjuvant treatment
- •Informed consent
- •Age 18-80 years
- •Karnofsky performance score > 50%
- •Neutrophil counts > 1 500/µl
- •Platelet counts > 100 000/µl
- •Hemoglobin > 10 g/dl
- •Serum creatinin < 1.5-fold upper normal range
- •ASAT or ALAT < 3-fold upper normal range unless attributed to anticonvulsants
- •Alkaline phosphatase < 3-fold upper normal range
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Progressive or recurrent glioblastoma documented by MRI earlier than 180 days after first surgery for glioblastoma and earlier than 90 days after completion of radiotherapy.
- •Any other prior treatment than temozolomide according to the schedule of the EORTC NCIC trial (Stupp et al. N Engl J Med 2005;352:987-996) except that an adjuvant starting dose of 200 mg/m2 as well as more than 6 cycles of adjuvant temozolomide are allowed
- •Allergy to or other intolerability of temozolomide
- •Unable to undergo MRI
- •Prior systemic or local treatment with DNA-damaging agents, tyosine kinase inhibitors or anti-angiogenic agents for any cancer
- •Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation
- •HIV infection
- •Breast feeding
- •Treatment within in any other clinical trial parallel to the treatment phase of the current study
研究者
相似试验
进行中（未招募）
不适用
Dose Intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma (DIRECTOR)EUCTR2008-006871-60-ATniversity Hospital Heidelberg, Ruprechts-Karl-University Heidelberg166
已完成
2 期
Dose-intensified rechallenge with temozolomide, one week on one week off versus three weeks on one week off in patients with progressive or recurrent glioblastomaCancerISRCTN68738654niversity Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)166
进行中（未招募）
1 期
Extended schedule, escalated dose Temozolomide versusDacarbazine in Stage IV Metastatic Melanoma: ARandomized Phase III Study of the EORTC MelanomaGroupEUCTR2004-000654-23-ESEORTC850
进行中（未招募）
不适用
Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma GroupStage IV Metastatic MelanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2004-000654-23-GBEORTC850
进行中（未招募）
不适用
Extended schedule, escalated dose Temozolomide versusDacarbazine in Stage IV Metastatic Melanoma: ARandomized Phase III Study of the EORTC MelanomaGroupStage IV Metastatic MelanomaMedDRA version: 7.0Level: PTClassification code 10027480EUCTR2004-000654-23-BEEORTC850